Age-dependent prevalence of antibodies cross-reactive to the influenza a(H3N2) variant virus in sera collected in Norway in 2011

Eurosurveillance

Volumn 17, Issue 19, 2012, Pages 1-5

  Waalen, K ^a   Kilander, A ^a   Dudman, S G ^a   Ramos Ocao, R ^a   Hungnes, O ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTINATION INHIBITING ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANIMAL CELL; ANTIBODY TITER; ARTICLE; CHILD; HUMAN; IMMUNITY; INFANT; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; NEWBORN; NONHUMAN; NORWAY; SEROPREVALENCE;

EID: 84862734223     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. World Health Organization (WHO). Standardization of terminology for the variant A(H3N2) virus recently infecting humans. Joint announcement of FAO, OIE and WHO. Geneva: WHO; 23 Dec 2011. Available from: http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/en/index.html
2. Centers for Disease Control and Prevention (CDC). Limited human-to-human transmission of novel influenza A (H3N2) virus - Iowa, November 2011. MMWR Morb Mortal Wkly Rep. 2011;60(47):1615-7.
3. Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v Transmission and Guidelines - Five States, 2011. MMWR Morb Mortal Wkly Rep. 2012;60(51):1741-4.
4. Lindstrom S, Garten R, Balish A, Shu B, Emery S, Berman L, et al. Human Infections with Novel Reassortant Influenza A(H3N2)v Viruses, United States, 2011. Emerg Infect Dis. 2012;18(5):834-7.
5. Centers for Disease Control and Prevention (CDC). First H3N2 Variant Virus Infection Reported For 2012. Atlanta: CDC; 12 Apr 2012. Available from: http://www.cdc.gov/flu/spotlights/h3n2v-variant-utah.htm
6. Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM, Webster RG. Evolution of swine H3N2 influenza viruses in the United States. J Virol. 2000;74(18):8243-51.
7. Lina B, Bouscambert M, Enouf V, Rousset D, Valette M, van der Werf S. S-OtrH3N2 viruses: use of sequence data for description of the molecular characteristics of the viruses and their relatedness to previously circulating H3N2 human viruses. Euro Surveill. 2011;16(50):pii=20039. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20039
8. Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill. 2010;15(31):pii=19633. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19633
9. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69-75.
10. World Health Organization (WHO). Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits. Geneva: WHO; 2011. Available from: http://www.who.int/influenza/resources/pip_framework/en/index.html
11. Morens DM, Burke DS, Halstead SB. The wages of original antigenic sin. Emerg Infect Dis. 2010;16(6):1023-4.
12. Skowronski DM, De SG, Janjua NZ, Gardy JL, Gilca V, Dionne M, et al. Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. Euro Surveill 2012;17(4):pii=20066. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20066
13. Centers for Disease Control and Prevention (CDC). Antibodies Cross-Reactive to Influenza A (H3N2) Variant Virus and Impact of 2010-11 Seasonal Influenza Vaccine on Cross-Reactive Antibodies - United States. MMWR Morb Mortal Wkly Rep. 2012;61:237-41.
14. Black S, Nicolay U, Vesikari T, Knuf M, Del GG, Della CG, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30(12):1081-5.